There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

Biologics Quality Control: The Growing Need for Accessible Proteomics

The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.

Emerging Therapies Drive Analytical Advancements

Effective analytics will eliminate failures, deviations, and non-conformances.

 Analyzing Exabytes

Topic

Articles

The BioProfile FAST CDV is a fully automated viable cell density and viability analyzer.

Nova Biomedical Launches Cell Density and Viability Analyzer

Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.

Pfizer and Gero Form Collaboration to Discover Potential Targets for Fibrotic Diseases

The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.

AbbVie and Anima Biotech Partner on Discovery and Development of mRNA Biology Modulators

Mark Eller, PhD, is senior vice-president (SVP) of Research and Development at Aria Pharmaceuticals. Eller has held several vice-president/SVP roles leading teams from discovery through approval at large and mid-sized pharma companies, including Jazz, Quintiles (now IQVIA), and HMR (now Sanofi). Eller is co-inventor on 30 patents and has led health authority presentations and negotiations, including six FDA advisory committee meetings. He has co-authored numerous scientific publications and served as an adjunct professor of Pharmaceutics at the University of Cincinnati. Eller received his Pharmacy degree and PhD in Pharmaceutics from the University of Iowa.

Advancing the use of AI to understand the whole of a disease can reveal drug development insights that lead to drug discovery breakthroughs.

Technology as a New Evolution in Fighting Disease

Feliza Mirasol is the science editor for 

PK/PD studies are a crucial tool in the successful development of biologics.

PK/PD Studies Prove Critical for mAb Development

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As the therapeutic landscape grows more complex, so too must the analytical techniques for cleaning validation to ensure the utmost cleanliness is achieved.



Cleaning Up in Bio/Pharma

The launch of Discovery Life Sciences’ new Proteomic Services Division offers a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis.

Discovery Life Sciences Now Offers Large-Scale Proteomic Services

Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.

Generate Biomedicines Uses AI to Create Proteins That Have Never Existed

PictorLabs, a digital pathology company developing an AI-powered virtual staining platform, formally announced its launch at the start of December.

Virtual Staining Start-Up Launches with More Than 18.8 Million in Funding

The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.

Analytics

Biologics Quality Control: The Growing Need for Accessible Proteomics

Emerging Therapies Drive Analytical Advancements

Analyzing Exabytes